Roper Technologies Inc
F:ROP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
470.5
532.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
You don't have any saved screeners yet
Good morning. The Roper Technologies Second Quarter 2020 Financial Results Conference Call will now begin. All participants will be in a listen-only mode. [Operator Instructions] Please note this conference is being recorded.
I would now like to turn the conference over to Zack Moxcey, Vice President, Investor Relations. Please go ahead.
Good morning and thank you all for joining us as we discuss the second quarter financial results for Roper Technologies. We hope everyone is doing well. Joining me on the call this morning are Neil Hunn, President and Chief Executive Officer; Rob Crisci, Executive Vice President and Chief Financial Officer; Jason Conley, Vice President and Controller; and Shannon O’Callaghan, Vice President of Finance.
Earlier this morning, we issued a press release announcing our financial results. The press release also includes replay information for today’s call. We have prepared slides to accompany today’s call, which are available through the webcast and are also available on our website.
Now, if you’ll please turn to Slide 2, we begin with our Safe Harbor statement. During the course of today's call, we will make forward looking statements which are subject to risks and uncertainties as described on this page, in our press release, and in our SEC filings. You should listen to today's call in the context of that information.
And now, please turn to slide three. Today, we will discuss our results for the quarter primarily on an adjusted non-GAAP basis. Reconciliations between GAAP and adjusted measures can be found in our press release and in the appendix of this presentation on our website.
For the second quarter, the difference between our GAAP results and adjusted results consists of the following items; amortization of acquisition-related intangible assets, purchase accounting adjustments to acquired deferred revenue, our restructuring charge associated with certain businesses in our Process Technologies segment. These were additional structural actions not contemplated in our prior guidance, transaction related expenses for completed acquisitions. And lastly, we have adjusted our cash flow results to exclude income tax payments deferred from Q2 to Q3 due to COVID-19.
And now, if you’ll please turn to slide four, I will hand the call over to Neil. After our prepared remarks, we will take questions from our telephone participants. Neil?
Good morning, everyone. And thanks for joining us. We hope that everybody listening or reading are doing well and enjoying the summer.
With that, let's go ahead and start with their agenda. As usual, we'll start with the enterprise highlights from the quarter, which are quite good given the health and economic challenges associated with the current pandemic. I'll then walk through our key financial and operational levers on a segment basis, and compare how we did versus what we thought heading into the quarter. Rob will then than discuss our P&L, our balance sheet, our cash position.
We find ourselves in a very fortunate position to have well over a $1.5 billion of cash on the balance sheet, and a completely undrawn $2.5 billion revolver. Following Rob's remarks, I'll walk through our detailed segment review and out Look, followed by our Q3 and full year guidance. And finally, I'll conclude with the highlights for the quarter and discuss our outlook for continued capital deployment. We'll then look forward to your questions.
Now let's turn to a brief run through of our Q2 results. Next slide, please. To start, I'm very proud of how Roper performed in the quarter, both on an operating basis and a balance sheet basis. On an operational basis, our revenues declined 2% in the quarter and 3% on organic basis. We saw organic growth in each of our two software segments. In addition, and as we force our last quarter, we saw very strong demand for our medical product businesses and laboratory software mostly used in a global fight against COVID-19.
Worth noting and broadly, our businesses did not experience much if any supply chain disruption in the quarter, which contributed to our revenue performance. We also saw gross margins increase 70 basis points to 64.7%. EBITDA margins were impressively flat versus a year ago at 35.3%, and DEPS was strong and came in at $2.94. Most importantly, free cash flow increased 10% to 315 million.
Specific to our balance sheet two items of importance, first, we successfully completed a $600 million, 10 year, 2% bond offering in the quarter. Also we're able to deploy $150 million for two bolt-on's indicating the window for capital deployment is reopening. More on these deals as we turn to the segment pages. So while 3% organic revenue declines are certainly below normal. Given the macroeconomic backdrop heading into the quarter, I'm very pleased with this performance, especially as it relates to our margin performance and cash flow.
To this end this quarter's performance serves as a great example, to illustrate the intimate knowledge each of our teams have with their business, their customers, their supply chains, and their employees. As we said, for many years, nimble execution yields great results. And that is certainly the case for this quarter and so far, this year. As we'll discuss later, in the call, we're maintaining our full year organic revenue outlook to be plus or minus flat, which we believe is a testament to our decade long business model transformation.
In addition, our greater than 1.5 billion cash position, and our undrawn $2.5 billion revolver allows us to be offensive relative to capital deployment. Our M&A pipeline remains full of high-quality opportunities. And prior to turning to the next slide, I want to thank our entire leadership team and our 16,000 employees for your tremendous work this quarter. Thank you.
Next slide, please. Turning to the second quarter segment results summary, this page summarizes our key business model levers and how they performed in the quarter. Starting with Application Software, we expected revenues to be down mid-single digits in the quarter, but actually grew 1%. As we did expect, renewal rates remain high and recurring revenues remain strong. Also, we did see strong demand across our laboratory software businesses, as they worked aggressively to enable scores of COVID-19 related testing capability on a global basis.
A good guy for the quarter was our software license sales, we saw across the segment better than expected conversion of perpetual ILF sales pipelines. A further positive variance was the success our teams had in implementing our software remotely, which led to higher service utilization rates and revenues. So this segment performed better than expected based on these two factors better license sales and higher service utilization rates.
For our network segment we expected to grow low single digits and did coming in at 2%. For the software businesses in this segment just about what we expected, high levels of recurring revenues and renewal rates and decent network expansions at ConstructConnect and DAT. More on this later, but the TransCore New York City congestion pricing infrastructure project continues to push to the right impacting more the second half versus this quarter.
As for the MAS segment, we expect it to decline mid-single digits, but did modestly better, only declining 1% in the quarter. Verathon and IPA outperformed our expectations and was driven by exceptional demand for their products and solutions throughout the quarter. As expected, our other medical product businesses were negatively impacted and continue to be negatively impacted by reduced elective hospital procedures.
Neptune performed in line with expectations and was down given that it had limited access to meters, especially in Canada and the Northeast United States where meters are installed inside residences. Finally in the segment, we saw sharp declines as expected in our industrial businesses.
Turning to our Process Tech segment, we were down 26% in the quarter, versus an expectation of being down plus 30%. The businesses in this segment perform generally as expected, slightly better than we thought at PAC and AMOT. Finally, the better than expected revenues levered very well the EPS, but DEPS coming in at 2.94 versus our guidance range of 2.50 to 2.70.
After Rob's comments, I'll come back and discuss in more detail our segment by segment performance. Rob, I'll turn it over to you.
Thanks, Neil. Good morning, everyone. We appreciate your interest in Roper Technologies as always. So turning to page seven, looking at our Q2 income statement performance, Q2 organic revenue declined 3% versus prior year with total revenue coming in at 1.306 billion.
We had positive organic revenue growth in both Application Software and Network Software and Systems, while sharp declines and our smallest segment Process Technologies pulled our overall organic growth into low single digit negative territory for the quarter.
Margin performance, as Neil mentioned, was a standout in the quarter as our businesses expanded gross margin by 70 basis points to 64.7% and held EBITDA margins flat at 35.3%. As a result, EBITDA declined only 2% to 461 million.
Our tax rate came in at 22.3%, a little higher than last year, resulting in adjusted diluted earnings per share of $2.94, which was well above our guidance range of 2.50 to 2.70, so in summary, really good execution by our business leaders in a very challenging environment.
Next slide, turning to page eight and looking at cash flow, cash flow performance for the quarter was very strong. On a GAAP basis, our operating cash flow was 449 million, which represented a 49% increase over last year.
However, for better compatibility and clarity, we are adjusting our results for the 124 million of income tax payments that were deferred from Q2 to Q3 due to COVID-19 and those taxes were subsequently paid in July.
So after adjusting for the timing of the 124 million of tax payments that pushed to July, our Q2 operating cash flow grew 8% to 325 million, which represented 25% of revenue.
Q2 free cash flow grew 10% to 315 million, which was 24% of revenue. Looking back at the past two years, our Q2 free cash flow has compounded a strong 12%.
Congrats and a special thank you to the finance teams at each of our businesses for continuing to make cash flow and cash collections a high priority. It truly was outstanding cash Flow performance in a challenging environment.
Next slide, turning to page nine and our asset light business model and negative working capital slide. We exited the first quarter with working capital of minus 4.4% and in Q2 we further improved this metric with working capital as a percent of revenue moving to minus 5.4%.
While we're certainly happy as always, to see our income statement hold up well in Q2, we believe it's just as important if not more important, that our cash flow and working capital metrics also remain strong.
In fact, as we continue to improve on these important working capital metrics, despite the challenging macro environment, this bodes very well for our ability to compound cash flow at higher levels as the economy does eventually rebound from the pandemic.
Next slide, turning to page 10, our strong financial position, so it's really a continuation here of the same story we discussed last quarter. Roper's liquidity position and balance sheet remained very strong. We ended June with over 1.8 billion of cash on the balance sheet.
To date in July as mentioned, we have made some tax payments about $316 million of tax payments have been paid to date in July. That's the previously mentioned 124 million of deferred payments as well as 192 million of taxes due on the gain from last year's Gatan sale.
So after making these payments, our cash balance today is approximately 1.6 billion and our $2.5 billion revolving credit facility remains fully undrawn.
In June, we took advantage of historically favorable conditions in the bond market and issued 600 million of 10-year notes at a coupon of 2.0%. At the time, we tied the record for the lowest coupon ever issued by a Triple B issuer.
Really great execution by our team and nice to once again see very strong demand for Roper bonds driven by our consistent ability to generate cash flow, high levels of recurring revenue and our diversified portfolio of asset light businesses.
At the end of the quarter our net debt to EBITDA stood at 2.1 times. And with our large cash balance and fully undrawn revolver, we remain very well positioned with significant financial capacity to take advantage of our large pipeline of acquisition opportunities.
So with that, I'll turn it back over to Neil.
Thanks, Rob. Let's go ahead and turn to our Application Software segment. Revenues here were 398 million up 1% on an organic basis, and EBITDA was 172 million or 43.1% of revenue. To start, our retention rates and other recurring revenues remain strong in the quarter. In addition, we saw better than expected software license sales in the quarter broadly across Deltek, Aderant and PowerPlan. Of note, sales pipeline bill that occurred prior to the quarter converted at a higher than anticipated rate. In addition and discussed earlier, we saw better service utilization rates and revenues than expected.
Our laboratory software businesses Sunquest, Data Innovations and Clinisys all grew and performed nicely aided by the global demand to deploy diagnostic testing software interfaces and laboratory software associated with combating COVID-19. Specific to Sunquest, we received the termination fee payment for the Queensland project in the quarter. As a reminder, last quarter, we noted that the customer opted to terminate this implementation in the face of COVID-19 related challenges.
CBORD, which is our software business that sells nutrition and food management software, as well as campus access solutions to hospitals and universities did decline, given their very limited access to both hospital and university clients. Broadly across this segment and of note, we are absolutely seeing an increased desire from our customers to migrate to our cloud or SaaS offerings, one of several trends that COVID appears to be accelerating. This should be a long-term growth driver for our business, as we have a large installed base of customers who will over time migrate to the cloud.
And turning to the outlook for the segment, we expect to be roughly flat on organic basis for the second half of the year, with the third quarter facing a challenging prior your comp specific to perpetual license revenues. We continue to expect high levels of recurring revenue retention. As a reminder, the vast majority of our customers in this segment are enterprise or larger companies. Furthermore, we serve a diversified and durable set of end markets, most notably government contractors, marketing services firms, law firms, utilities and hospitals. That said we do anticipate some continued pressure on our new logo software license sales.
This quarter's license revenues were aided by sales pipelines that were built pre-COVID and converted better than expected in the quarter. The second half funnel is increasingly comprised of post-COVID shut down activity. As a result, we expect our prospects decision timeframes may extend longer than our historical experience. That said we are encouraged by the fact that the top of the funnel activity looks good, and we liked the MQL, SQL conversion rates. But again expect decision timing could be more elongated than normal.
With that next slide, please. Turning to our Network segment, revenues grew 2% organically to 423 million and EBITDA was 176 million or 41.5% of revenue. As a reminder, most of our software businesses in this segment share highly recurring SaaS revenue models, which are further aided by strong network effects that drive higher retention rates and network ads, which were certainly the case in this quarter.
To this end, our ConstructConnect network expanded in the quarter and was driven by strong customer ads and network utilization. As a reminder, our ConstructConnect business's primary product provides building contractors with all available commercial building projects that are in the planning phase and enables them to bid and win work. In an economic environment like this one, the value of this product further increases.
Our DAT business grew high single digits in the quarter led by large number of carrier additions to the network and strong growth in our rate data offering. To add to our rate data product capabilities, we acquired FMIC in the quarter. FMIC is the leading benchmarking and rate analysis firm focused on the contract freight market. When combined with DAT the FMIC data sets will be a unique product offering that benchmarks both the contract and spot truck freight markets in the US. In addition to FMIC, we also acquired Team TSI. We're integrating team TSI with our SHP business.
When complete, the combined business will have a comprehensive operating, financial and quality benchmarks that span the continuum of post-acute care, namely skilled nursing and home health. In addition to helping the post-acute providers operate their businesses more efficiently, SHP will help improve patient outcomes through innovative real time data and evidence-based collaboration among acute care providers and their post-acute partners. We're excited to see this strategy unfold. As mentioned earlier, these bolt-on acquisitions have a combined purchase price of 150 million.
Turning to last year's acquisitions and it's worth noting that Foundry and iPipeline continue to perform well and are proving to have quite resilient business models as we expect. As we look to our rf IDEAS and Inovonics businesses, they were challenged in the quarter directly resulting from having limited access to customers. And finally, the TransCore New York City congestion pricing infrastructure projects continues and is deemed essential. However, the project at the election of our customer has slowed and continues to push into 2021. Execution of the project remains strong, but the time is elongating.
Turning to the outlook for the segment, we see mid-single digit organic growth in the second half. Relative to Transport and the New York project as mentioned, we see this project pushing to the right, notably about $0.20 of DEPS is being pushed into next year as compared to what we thought a quarter ago. That said, we continue to see growth and resiliency in our Network Software businesses driven by higher recurring revenues, strong retention rates, expanding networks and solid network participation.
Next slide please. Turning to our Measurement and Analytical segment, revenues declined 1% organically to 364 million and EBITDA was 132 million or 36.2% of revenue. In the current environment this segments activities are best broken into four boxes, one, Verathon and IPA; two, other medical product businesses; three, Neptune and four, our industrial businesses. First, Verathon and IPA, both experiencing tremendous demand for their products directly attributable to hospital demand resulting from COVID-19.
Verathon experienced strong demand for their GlideScope video intubation products. As a result of COVID-19 the percentage of all intubations not just COVID related that are being done using video assistance has meaningfully increased. Verathon's demand is both for capital systems, which means an expanding customer base and the pull through consumables. We have to give hearty congratulations to Earl, Tracy, Tim, Jeff and the entire team at Verathon.
It's one thing to have unprecedented demand. It's a completely different thing to be able to flex the supply chain to fulfill the demand within a single quarter. Congrats and thanks to the Verathon team. A similar story with IPA, hospitals rapidly adopted their automated scrub distribution systems to help deploy scrubs more broadly to staff within the hospital setting.
Second, and relative to our other medical product businesses, we did see revenue headwinds tied directly to government mandated lower patient volumes within acute care hospitals on a global basis. We also want to note that this group of companies consistently grows mid-single digits, but this growth is conditioned on regular hospital admissions patterns.
Third, Neptune was negatively impacted by restricted access to indoor meters in particular in Canada, in the Northeast United States. And finally, and as expected, we did experience a sharp decline in our short cycle industrial businesses. However, in the second half of the quarter, we did see modest improvements in consumable demand.
As we turn to the second half outlook, we expect to see mid-single digit growth in this segment led by continued strong demand at Verathon for the reasons just discussed. In addition, we expect to see reduced levels of non-emergent capital procedures providing continued headwinds for a non-Verathon and non-IPA medical product businesses. We do expect to see improvements in Neptune on easing lockdowns, especially in the Northeast United States, which will provide better access to indoor meters. Also, we're cautiously optimistic given that July municipal budgets appear to be largely intact. And finally, we expect to see gradual improvements in our short cycle industrial end markets.
Next slide, please. Turning to our Process Technologies segment, revenues were 121 million in the quarter, down 26% on organic basis and EBITDA was 33 million or 27.4% of revenue. This was certainly a difficult quarter for these businesses and we expect the outlook to remain poor for the balance of 2020. Despite a uniquely challenging environment for these businesses, they still had high 20% EBITDA margins in the quarter. And our leadership teams have done a great job of navigating these end markets and continuing to make no regrets investments.
We saw our upstream businesses decline approximately 40% in the quarter. Our PAC business also declined, and it was related to weak fuel demand in the quarter. As a reminder PAC is our laboratory fuel analysis business. Also, CCC was weak based on the inability to perform field service work, all related to COVID-19. One bright spot in the quarter was Zetec, which experienced growth based on the strength of their new non-destructive testing products.
Also in the quarter, we initiated targeted restructuring actions across a few of our businesses in this segment, which resulted in a $13.6 million charge. None of these structural changes were considered in our guidance from a quarter ago. These actions will position these businesses to better serve its customers and realize longer term savings. While the oil and gas markets and customer commitments remain more muted, we believe this is the right time to execute these restructuring activities.
The outlook for the balance of the year continues to be an extremely challenging one, as we expect to see approximately 25% organic decline for the second half. Specifically, we do not anticipate any recovery in upstream oil and gas markets and expect upstream to account for less than 40 million of revenues in the second half. In addition, we expect to continue to have limited customer access, which hampers our ability to perform field service work.
Next slide please. As we turn to our guidance, we're narrowing and modestly raising the midpoint of our full year adjusted DEPS guidance to be in the range of 11.90 and 12.40 per share. We continue to guide full year organic revenues to be plus or minus flat. In addition, we're initiating DEPS guidance for 3Q in the range of 2.90 to $3.
Now let's turn to our summary and get to your questions. Next slide please. Given the global pandemic and associated shutdowns in the quarter, we're pleased with our performance, with revenue only being down 3% organically, EBITDA margins holding flat versus the prior year at 35.3% and cash flow growing 10% to 315 million.
From an operating point of view, our businesses remain focused on employee health and safety continue to improve the efficiency of remote work, to remain super intimate with our customers and continue to focus on long-term durable growth. To this end, our businesses continue invest in growth oriented operating initiatives.
Our leaders, all of whom are long-term builders are masterful at maintaining product investments during down cycles, which oftentimes lead to market share gains upon recovery. As a leadership team, we remain steadfastly committed to this concept. For the full year, we expect to have plus or minus flat organic revenue growth.
We believe our portfolio of businesses and our governance processes continue to be well suited to navigate these difficult times. Our balance sheet is stronger than at any point in history with over $1.5 billion of cash and $2.5 billion of revolver capacity. And specific to capital deployment, we do have a high quality and active pipeline of opportunities as private equity sellers have recently re-entered the market.
That said and as always, our CRI based strategy focus is on long-term cash flow compounding, and we will continue to patiently evaluate and pursue capital deployment opportunities that are consistent with this strategy. And as we turn to your questions, I remind everybody that what we do is very simple. We compound cash flow by operating our portfolio of businesses that have leading positions and niche markets that have the proven ability to generate increasing cash flow as their businesses expand.
We provide our business leaders with Socratic coaching about what great looks like relative to driving long-term CRI accretive organic growth, with particular emphasis focused on strategy, operations, innovation and talent development. Our business leaders understand that success in our culture is based on their ability to compete and win for talent and to compete and win for customers that in turn allow us to compete and win for shareholders.
To this end, we incent our management teams based on growth. And based on these factors and perhaps most importantly, we have a culture that is rooted in the principles of mutual respect, trust and transparency. And finally, we take the excess free cash flow that is generated by our businesses and deploy to buy businesses that have better cash returns on our existing company that in turn helps accelerate our cash flow compounding. It is these simple ideas that deliver powerful results.
And with that, now let's turn to your question.
We will now go to our question-and-answer portion of the call. [Operator Instructions] The first question comes from Deane Dray of RBC Capital Markets. Please go ahead.
Thank you. Good morning, everyone.
Good morning, Deane.
Hey, Deane.
Can we start with the congestion tolling project? Can you just give us some context of this latest push out? It would be fair to assume that just logistically COVID is presenting issues in terms of being able to work on the project. But is there been any change in scope that's being considered?
No. Hey, Deane. No change whatsoever in the scope, the contract value that we talked about a few quarters ago remains the exact same. And so the only thing that is happening here is the project is pushing a bit to the right into 2021 for the reason you said, a little bit access to personnel related to COVID and a little bit just at the election of the customer line to paste the project a little bit. And I think also we highlighted last quarter, I mean, the motivation of the client is never been higher. I think it was just around this time last quarter. The proceeds from the project for 2021 and '22 could be used in MTAs operating budget where the initial project that was going to be used for capital only, so there is a clear motivation to get the – by the customer to get the project up and running. It's just slipping to the right a little bit.
Just to clarify, there was a discussion of push outs in the first quarter. So this $0.20 of EPS push out. This is new and incremental, correct?
That's correct.
Yeah, that's – yeah, that's correct Deane. So the project was originally around 200 million for this year, and now we've got about 110 or so million in for 2020. And as Neil mentioned, the rest is pushed to the right, and we expect to be completed in '21.
Got it and then second topic would be the net COVID impact across your businesses. And I'm sure this is a fair question to ask. But you listed a number of ways that Roper is positioned to help between the labs support system witnesses [ph], data innovations, the Verathon incubation systems, those would be the positives, but the negative is it all related to just the deferrals of non-emergency procedures. So how do those to net out if?
If your question is relegated to the medical product businesses versus price, if you relegate to that as a broader to Roper, I want to make sure I'm answering the question –
No, just the medical related, sorry.
Okay. Yeah. So it's a net – a meaningful net grower, right, when you look at the benefit of those of Verathon and IPA good guy against the bad guys of the other four or five medical product businesses aggregated together, it's a very meaningful positive, good guy. It's worth noting though, the Verathon demand while it certainly surged in the quarter, the team worked really well to work down the backlog a little bit more to go in the second half of the year. The team that Verathon believes that the demand is – will endure a bit right. It's about the number, the percentage or the market share of global incubations that are being done with video assistance versus not. Going into the pandemic, it was somewhere in the 15% of all intubations were done with video assistance and 85 direct. And that market share video is going – it's meaningfully higher now and it will stay. It'll be meaningfully above 15% on the backside of this, so the market just grew, we believe, for these products that Verathon has.
That's real helpful. Thank you.
Thank you.
The next question comes from Scott Davis of Melius Research. Please go ahead.
Hi, good morning, guys.
Hey, Scott, good morning.
Hey, Scott.
I was trying to get a sense and a little bit of follow up on Deane's question, but trying to get a sense of ConstructConnect. You commented out the pandemic, perhaps helped – is helping catalyze some growth there. I mean, very few of us are experts in many of these businesses. I'm certainly not an expert in ConstructConnect by any stretch of imagination. But can you give us a sense of how that business grows in this type of environment? Is it – well, I'll just leave a little bit of that just open ended, how does it grow and how much does it impact? Is there any way to – the magnitude, the pandemic really helping get word of mouth or otherwise out there on the product.
Yeah, happy to talk through that, so just to remind you and everyone ConstructConnect, the primary part of the business all for non-residential or commercial construction in the United States and Canada that's in the planning phase. So once a shovel goes in the ground, other constituents in the value chain pick up that. This is about planning. It allows general contractors, subcontractors, building product manufacturers to be aware of the projects are being planned, so they can bid for and win those projects and we have software that organizes all of that activity. So when the market is raging hot, right, all the subcontractors have more work and they can possibly do the value of leads or what new projects is lower, right.
And so we've always sort of said, if there's five market conditions, five is white hot and one is there's basically zero construction, that constructing that value proposition is best in positions two, three and four, right, where there's work and activity going on, but not so much work that contractors have so much to do, right. And so, what's essentially happened here and ConstructConnect reports on this and Zach can give it to you is, nonres construction activity is down 28% versus prior year. It was up a little bit in June versus May. But that's the exact environment where the value proposition of leads and project awareness sort of thrives. And that's why you saw more contractors come into the ConstructConnect market and grow in the quarter.
I would just add to that it's a SaaS business, Scott. So there's not huge swings in the revenue like you get with a perpetual license bid. We're seeing increased activity in the network and that leads to a little bit of more subscriptions, more customers, and then over time, that drives additional growth with the business.
Right and those custom customers, I mean, do they come in and then they generally stick around or they come out when economic conditions get weaker?
Really appreciate the question. So history, if you go way back in the ark of ConstructConnect, some of them will stay and some of them will leave. But since our ownership in '16, the ConstructConnect team has worked really hard to build habituation into the product, if you will. So now there's integrated takeoff which is the estimation process and directly linked and so we believe the customers when we look at the utilization of the product, they're in the product on a multi time a day basis now, where five, six, seven years ago, they'd be in the product only when they needed to look for any project. And so we believe based on that the sort of the long-term retention rates of the business go up.
Okay. Okay, super helpful. Okay. Congrats guys. Good luck this quarter.
Yeah. Congrats on the book as well.
Thank you.
[indiscernible] Please go ahead, sir with your question.
Hey, can you hear me okay?
We can Steve. Hey, I think its Steve, right? Yeah, okay.
Yes. Sorry. Sorry guys, just managing some things here. Like eight different calls. Just on the acquisitions you recently did. Can you just give us some color on the revenues and what you paid for those, just general multiples for some of the ones you've done?
Yeah. Sure, Steve. So there's the two acquisitions in the quarter, combined purchase price about 150 million. And we've got about 25 million or so revenue in the model for '21. And EBITDA margins there in the mid to high 40s. So pretty good cash, but each business is being integrated into a business. So there was not a lot added for the second half, but there's some integration going on, but that built a real good strategic adds to the Roper businesses.
Got it and then just a last one on the – on some of the – I think you guys had expected a bit weaker performance in some of the software businesses. I know you went through some of this in the prepared remarks. But is there anything that kind of gives back a little bit in the second half that notable and it's material in any of those software businesses that just perhaps some differed downside relative to what you would have expected in the second quarter, some timing items?
So in the second quarter, I mean, yeah, I think the second quarter software for the reasons we said on Application Software, I mean, it was the better utilization rates on the service side. And we expected more deferral or push outs of the license activity. And that proved to be a little conservative. And so that was broad that license activity was brought across Deltek, Aderant, PowerPlan. We saw good performance across the diagnostic businesses that we just talked about. Excuse me, some of that – a lot of that was COVID related.
Right, yeah, there's a lot of good – good things that happened in acute care software in the quarter which are driven by the demand around COVID. Right, so that's – some of that stuff happened in the second quarter that we didn't expect. And we'll see what continues into the second half, but that's difficult to predict.
Steve, was there a follow up?
Sounds like he went on, okay.
Understood, the next question comes from Julian Mitchell of Barclays. Please go ahead.
Hey, good morning, everyone. This is Jeff Alvaro [ph] on for Julian.
Okay Jeff.
Maybe just to start Application Software margins came in pretty strong for the quarter, can you just give some color on what contributed there? And maybe as part of that, just your thoughts on how margins look there in – at other segments for the second half?
I'll take the first part of that. Let Rob take a second. Hey, it's directly – the Application Software margin performance in the quarter is directly tied to better license activity as you know, perpetual licenses in quarter are super high margin, 90 plus percent, 85%, 90%, so when they perform an expectation on license, and you tend to have better margin performance.
And then we also received the Queensland payment for Sunquest, which put revenue and large high margin net revenue in the second quarter as well, which helped. And then as we look at the second half the margins don't move around a lot in the other segments, which is a great thing, right. It's high recurring revenue, very stable business models you don't get this sort of swaying, so we certainly expect EBITDA margins to be sort of flat or a little bit better year-over-year in the software segment.
Perfect. And then some interesting comments you guys mentioned, municipal budgets seemed to be intact so far. Any thoughts on how much this holds in the second half? And then maybe thoughts on what level of potential cuts you guys are dialing in for kind of your outlook next year? I know that's a bit early. And then maybe just as part of that, can you just remind us kind of what percentage of sales within M&A as it's kind of tied to municipal budgets?
Very low dollars percent of revenue, I mean, it's going to be the part of Neptune that swings around with budgets. And Neptune's a pretty stable high recurring revenue business. So it's a real small percentage of the segment in single digits, it's going to really be driven by swinging budgets.
Yeah, and more broadly coming – this time last quarter in the height of the shutdown, a risk item that we – or were flagged was our Neptune's customers budgets going to be intact as they rolled into their New Year's because a large percentage of these customers have a July 1 fiscal year just given the broader economic challenges that municipalities and cities are experiencing. The good news is the budgets appear to be largely intact, so that high – the first risk item appears to be mostly retired. Remaining risk item is now the spend against the budget, right and that's to be determined, but the first step is a checkmark and we'll see how things unfold the rest of the year.
Got it, thank you guys.
Yeah, thank you.
The next question comes from Joe Ritchie of golden. Please go ahead.
Thanks. Good morning, everyone.
Hey, good morning.
Hey, Joe.
Hey, Neil, maybe just some commentary on the elective procedure impact in the quarter and obviously, like things are still incredibly fluid with the virus, but I'm just trying to understand, maybe how much of this pushes out into 2021 and whether there's like a revenue boost in 2021 once hopefully, elective procedures come back.
Yeah. So the products – the companies that we have that are somewhat indexed to procedure volume, its one derivative behind it, right. So very little of our businesses are consumable in a procedure, but our capital and products are used by other companies who are – and used in a procedure. And so we're buffered a little bit by what our customers are seeing. We did see a little bit in the second, maybe the June time period, some of the true consumables sort of pick back up. And that's just going to be evolved for the balance of the year. We would expect, as I mentioned, the open continent the prepared remarks, I mean, this group of businesses going back for many, many years grows like clockwork at mid-single digits, and that assumes a patient volume yet that are normalized and so to the extent volumes are normal in 2021, then we would see a pickup in that group of businesses.
Just to give you a sense Joe, so the sort of other medical products businesses which exclude Verathon and IPA, which have a huge COVID benefit, so everything else, those businesses were down double digits in the quarter, and they would normally be mid-single growers. And so I think we will catch up some of that at some point, but it's very difficult to predict when.
Got it, that's helpful, Rob and then just maybe my quick follow up. I thought your commentary around like the acceleration into cloud-based solutions was interesting. I guess, Neil, if you could maybe just provide some context for what that opportunity could be for you guys, either qualitative or quantitative that would be helpful.
Yeah, I'll leave it. It's sort of on the qualitative basis, right. So as we said for a long time, we – as a guiding principle, we allow our customers to pace the transition to the cloud, we don't force it or have a force product migration or just they're waiting for that to occur. We have some businesses like Strata that are born in the cloud. We have other businesses like Aderant and PowerPlan that are still vast, vast majority on-premise. And then we have companies like Deltek that are somewhere in between, right, sort of in the middle in their journey of the migration. What we've seen at Deltek is that that migration is a net growth driver. And we can talk about that in more detail later to the extent you're interested.
But you basically are taking a large installed base of customers who pay you annual maintenance and you're uplifting them to the cloud. So you're providing all the backbone and IT sort of management services, but also, you're doing all the release management, getting them on the most recent release. They're more micro releases. And so the customers get to take advantage of what you're actually developing. And that has real value associated within the mind's eye of the customers. And so for that reason, as they migrate from on-premise to cloud, there's an uplift in recurring, a pretty meaningful one and that's a that's a multiyear growth driver for our enterprise on Application Software or an Application Software.
Got it, that's super helpful. Thanks, guys.
Thank you.
The next question comes from Joe Giordano of Cowen. Please go ahead.
Hey, guys good morning.
Good morning.
Can you talk about maybe some of the implications of a potential infrastructure bill that might have maybe on, I'm guessing Deltek would be the most maybe PowerPlan, I'm not sure? But how that might impact the overall portfolio?
It's not – I think it would have a slight impact. And the reason I say that I'm looking at Rob and Shannon, it's not something we talked about right. And so about an infrastructure bill, we're not rooting for one so I think we're –
Yeah, I think the government contractors are always betting money on whatever there is to spend money on.
Yeah, Rob's point there is a very good one, right, so the contractors go where the fast flow is in a government spend. And so maybe you get a few more government contractors that could be dealt like customers, but that's not over yet [ph].
Okay, fair enough. Can you kind of just set a range kind of for us, I's assume like within – your software businesses did better than expected, obviously, but I'm guessing there's huge differences between businesses like CBORD where you couldn't go? Like people were on site like, can you kind of scale what are the – even if you don't want to get into the specific business names or like how big were some of the biggest declines and how big were some of the biggest gainers in the in flight?
Well, I'll set it up. I'll give you some context and let Rob sort of give you his view. So as we mentioned, last quarter in this segment, about 70% of revenues are recurring, 20% are tied to services and that's generally coming – working off some sort of six to 18 month backlog and then 10% of the revenue is that perpetual license. So the most short-term impacted is that 10%, so that tends to mute the magnitude of the swing in any given period of time, assuming that the in flight implementation projects don't stall. We see a lot of that block, if any of that activity in the quarter. So with that Rob?
Yeah, they are just very stable businesses. So I'm just looking through all the software businesses and sort of they're all kind of between a low single digit gain or low single digit decline, with the exception of CBORD, which is a little bit worse than that. So again, that a little bit better than expected because you know a huge part of the businesses are stable. The question is are you going to get any of these license wins in the quarter? Are you able to look to deliver services? And we were. And so to the extent that continues, that certainly helps us, there's just aren't big swings in these businesses, which of course, we had huge swings in the product businesses where there's more issues with not being able to access customers, et cetera.
Better, thanks, guys.
Thank you.
The next question comes from Alex Blanton of Clear Harbor Asset Management. Please go ahead.
Hi, good morning.
Good morning, Alex.
I wanted to ask about the push up in the TransCore business in New York City. You mentioned $0.20 going into 2021 from '20, a new $0.20. And then I think you said I want to confirm this, a 110 million now in this year versus 200 million before. So that's a $90 million push, is that – are those the right numbers?
They are Alex. So there was an interim step in there that last quarter with the 200 became 175. And now it's 110, so the move from 175 to 110 is your $0.20.
Okay, that's what I wanted to know. So that's a $65 million push out, generated $0.20 per share, push out, so we can calculate the incremental margin there. That's what I'm getting at.
These are all rough numbers, but yeah, go ahead.
Yeah, I know. Yeah. We don't need percentage. The second thing is, we haven't really – I don't think anyone asked about the acquisition pipeline. You've got max $4.1 billion of spending power for acquisitions. What does that look like? What are you working on, big, small, what's the timing? Is some of that getting pushed out because of COVID? What's the situation there?
Alex, appreciate the question. So I'll give you a little bit of context and color. So we had a pretty – the activity coming into COVID. I mean, it was as busy as we had been that I can recall since being here in 2011 in terms of what the funnel activity looked like. Obviously, everything shut down. I mean, when the credit markets shut down, everything shut down in April and May. It was there was really no activity anywhere. No sellers were selling anything for obvious reasons. But the end of May, first part of June we saw some green shoots, we obviously got these two bolt-on's complete, which are sort of in the pipeline pre-COVID. And really here since the middle of June, until now, it's almost as if we're back to January, February in terms of private equity seller interest in activity.
The private credit markets aren't fully back, but they're back enough to give sponsors confident that they can run a process or processes. And so we're encouraged by all that because we're sitting here with what you just said a large amount of cash and borrowing capacity to sort of continue this – our long-term CRI driven sort of compounding strategy. I will note the things that we see that – obviously, the things that come out of the shoot first after a slowdown are the very best assets, right, the ones that have the best niches, the best competitive position, the best highest level of recurring revenue, durability, things like that. And those tend to be fairly valued, right. There's not a lot of bargains that we would say we see in the software space, but values – valuations consistent with what we saw coming into the pandemic.
What accounts for the pickup? The COVID situation is actually worse than was in April. There's spikes all over the place and the government doesn't have control over at all. They're not even trying. So what accounts for the opening up of acquisition activity?
We can only speculate what's in the mind's eye of the sellers, right, but a couple of things. First is, the types of – everything I just said I should have qualified by saying our M&A pipeline is 100% software focused, right and so these are businesses even in the public markets that are proving to be resilient, sort of the comparables if you will and so that is – colors my comments on what a funnel activity looks like. The other thing is private equity sellers, which is where we buy 100% of our assets from have to return capital. They have limited sort of pressures. That's a constant drumbeat. And then finally, and this is me certainly speculating about private equities view of what might happen in election and taxes, but that certainly may be a motivating factor to get some things done by the end of this year.
Taxes, okay. Yeah. I don't remember the question, but now it slipped my mind.
Happens to me all the time.
Yeah. You said 100% software focused. I know what it was. Your sister company Dover Corp used to say that – one of the favorite things they said was that during recessions, they always gained market share because they had the dominant positions in their companies and their markets. And so weaker competitors would lose out some business and even go out of business during recessions. So Dover actually benefited from market share standpoint during economic downturns. How would you characterize Roper in that regard? And what is happening now, are you gaining share overall from people having a lot worse time than you are?
So we would echo those comments that companies like Roper in our history is we continue to invest in product through cycle, especially in the down cycle because your competitors oftentimes are not able to. We also stay super close to our customers, the vast majority of what we – our companies have direct channel access or a sap to work through a distributor so you stay super close to the customers and almost certainly on the back end, you can gain share either because of customer intimacy or because you develop or launch some new product or product capability, so 100% that is the case for Roper in this current environment.
Okay. And this is a tough one, but what percentage of this 4.1 billion do you think you might deploy this year?
That's real hard. Yeah, that's really impossible to predict. We're going to do the work we always do and we certainly have the capacity, but we only do the best deals and we never feel pressured. But certainly the balance sheet has never been stronger. So we feel good about our ability to deploy capital this year.
As our – my predecessors said many years ago, our discipline is only outmatched by our patience.
Okay, thank you very much.
Thank you.
Thanks.
This concludes our question-and-answer session. We will now return back to Zack Moxcey for any closing remarks.
Thank you, everyone for joining us today. We look forward to speaking with you during our next earnings call.
Conference has now concluded. Thank you for attending today's presentation. You may now disconnect.